COVID-19 News from Annals of Internal Medicine eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Message :
Required fields
ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a new class of interferon drugs, announces the strengthening of its Board and Management as well as a pre-IPO funding round to advance its lead novel hybrid interferon drug candidate Alfacyte™.
The appointments announced are Peter Bains as Non-Executive Chairman, Richard Morgan as a Non-Executive Director and Allan Watson as Chief Financial Officer.
Dr Magnus Nicholson, Chairman of ILC Therapeutics, will become senior adviser and non-executive director on the board.
These appointments will significantly strengthen ILC therapeutics’ Board and executive team as the company seeks to accelerate plans to advance its novel technology platform and prepare its lead candidate, Alfacyte™, for clinical trials.
ILC Therapeutics Announces Board Changes and Funding Round to Accelerate Covid-19 Drug
ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a new class of interferon drugs, announces the strengthening of its Board and Management as well as a pre-IPO funding round to advance its lead novel hybrid interferon drug candidate Alfacyte.
The appointments announced are Peter Bains as Non-Executive Chairman, Richard Morgan as a Non-Executive Director and Allan Watson as Chief Financial Officer.
Dr Magnus Nicholson, Chairman of ILC Therapeutics, will become senior adviser and non-executive director on the board.
These appointments will significantly strengthen ILC therapeutics Board and executive team as the company seeks to accelerate plans to advance its novel technology platform and prepare its lead candidate, Alfacyte, for clinical trials.
Among the most promising therapeutic options for individuals with coronavirus disease 2019 (COVID-19) are monoclonal antibodies (mAbs). In this study, Jones et al . identified, characterized, and tested one such mAb, LY-CoV555, in vitro and in vivo. They found that LY-CoV555 bound to the severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) spike protein and prevented its interaction with angiotensin-converting enzyme 2. Prophylactic treatment with LY-CoV555 protected the upper and lower respiratory tracts of nonhuman primates from becoming infected with SARS-CoV-2. Together, these data support the clinical use of LY-CoV555 for treating patients with COVID-19.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics that may bridge widespread vaccination campaigns and offer a treatment solution in populations less res
A new SARS-CoV-2 variant (HMN.19B) has been identified in France
New research published in the Centers for Disease Control and Prevention’s journal
Emerging Infectious Diseases has confirmed the emergence of a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant called HMN.19B from the viral clade 19B in France. The 19B viral clade which includes the D614G variant was prevalent in late 2019 but had since been rarely observed since early 2020 because of newer viral clades.
The variant is characterized by 18 amino acid mutations including N501Y, L452R, and H655Y. There is evidence the variant can spread more rapidly than other SARS-CoV-2 strains.